Efficacy of pretreatment with edaravone on cerebral blood flow in carotid artery stenting.

Efficacy of pretreatment with edaravone on cerebral blood flow in carotid artery stenting. - Efficacy of pretreatment with edaravone on cerebral blood flow in carotid artery stenting.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005303

Enrollment

Registered

2011-04-01

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carotid stenosis

Interventions

Patients will be randomly selected to receive edaravone. Intravenous administration of edaravone (60mg) before carotid artery stenting. Patients will also be randomly selected to receive treatment wit

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with carotid artery stenosis of 70% and more in symptomatic stenosis, and 80% and more in asymptomatic stenosis.

Exclusion criteria

Exclusion criteria: 1)Renal dysfunction(Cre>=1.5mg/dL) 2)Hepatic function disorder (AST>=100IU/L or ALT>=100IU/l,total bilirubin>=2.5mg/dL) 3)Plt<100,000/mm3

Design outcomes

Primary

Measure	Time frame
The change of cerebral blood flow using single photon emission computed tomography.	—

Countries

Japan

Contacts

Public ContactTakenobu Kunieda

Kansai Medical University Department of Neurology

kuniedta@hirakata.kmu.ac.jp0728040101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026